Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Sales | 3,722,411 | 4,958,793 | 4,935,779 | 5,088,579 | 4,816,122 |
| Cost of Goods | N/A | N/A | N/A | 1,291,410 | N/A |
| Gross Profit | 3,722,411 | 4,958,793 | 4,935,779 | 3,687,220 | 4,816,122 |
| Operating Expenses | 0 | 0 | 0 | 2,905,550 | 0 |
| Operating Income | 3,722,411 | 4,958,793 | 4,935,779 | 892,029 | 4,816,122 |
| Interest Expense | 0 | 0 | 0 | 9,760 | 0 |
| Other Income | 0 | 0 | 0 | 64,351 | 0 |
| Pre-tax Income | 3,722,411 | 4,958,793 | 4,935,779 | 946,620 | 4,816,122 |
| Income Tax | N/A | N/A | N/A | -157,720 | N/A |
| Net Income Continuous | 853,546 | 267,327 | 311,193 | 997,371 | -12,074 |
| Net Income Discontinuous | -391,640 | -31,552 | 98,090 | 121,334 | -448,226 |
| Net Income | $461,906 | $235,774 | $409,283 | $1,118,705 | $-460,300 |
| EPS Basic Total Ops | 0.29 | 0.15 | 0.26 | 0.71 | -0.29 |
| EPS Basic Continuous Ops | 0.54 | 0.17 | 0.20 | 0.63 | -0.01 |
| EPS Basic Discontinuous Ops | -0.25 | -0.02 | 0.06 | 0.08 | -0.28 |
| EPS Diluted Total Ops | 0.29 | 0.15 | 0.26 | 0.71 | -0.29 |
| EPS Diluted Continuous Ops | 0.54 | 0.17 | 0.20 | 0.63 | -0.01 |
| EPS Diluted Discontinuous Ops | -0.25 | -0.02 | 0.06 | 0.08 | -0.28 |
| EBITDA(a) | $3,722,411 | $4,958,793 | $4,935,779 | $892,029 | $4,816,122 |